Avenue Therapeutics (ATXI) Stock Price, News & Analysis

Company Overview

Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for acute and other serious medical conditions. The company is headquartered in the United States and trades on the Nasdaq under the symbol ATXI.

Avenue’s primary product candidate has been intravenous tramadol, an investigational formulation intended to provide short-term management of acute postoperative pain in adults who require an opioid analgesic in a medically supervised setting. The company has pursued regulatory approval in the United States and has conducted clinical and regulatory activities related to the product’s safety, efficacy and manufacturing.

Avenue Therapeutics was established as a subsidiary of Fortress Biotech, a biopharmaceutical company that supports the development of medicines through a subsidiary-based model. Its activities have primarily centered on advancing its lead acute-pain program through the U.S. regulatory process rather than operating a broad commercial product portfolio.

Key Stats

• Today's Range: $0.43 to $0.43
• 50-Day Range: $0.26 to $0.82
• 52-Week Range: $0.15 to $0.97
• Volume: 10 shs
• Average Volume: 6,726 shs
• Market Capitalization: $1.42 million
• P/E Ratio: 0.02
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 8/09/2024
• Today: 10/16/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ATXI
• CIK: 1644963
• Web: www.avenuetx.com
• Phone: (781) 652-4500
• Fax: N/A
• Employees: 4
• Year Founded: 2015

Profitability

• EPS (Trailing Twelve Months): ($0.85)
• Trailing P/E Ratio: 0.02
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.38 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -471.57%
• Return on Assets: -296.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.70
• Quick Ratio: 2.70

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.92 per share
• Price / Book: 0.22

Miscellaneous

• Outstanding Shares: 3,295,000
• Free Float: 2,017,000
• Market Cap: $1.42 million
• Optionable: Not Optionable
• Beta: -0.23